-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on AbbVie, Raises Price Target to $294

Benzinga·10/23/2026 18:03:10
Diffusion vocale
Goldman Sachs analyst Asad Haider maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $258 to $294.